The Food and Drug Administration approved the first single medication to treat hepatitis C on Friday, green-lighting one pill in the place of multiple treatments. The new drug, Harvoni, is the third hepatitis C drug approved in the past year.
“With the development and approval of new treatments for hepatitis C virus, we are changing the treatment paradigm for Americans living with the disease,” said FDA official Edward Cox.
Harvoni, developed by Gilead Sciences, will be the first hepatitis drug to require a pill only once daily. A full 12-week treatment will cost $94,500, less than existing treatments, Reuters reports.
More Must-Reads from TIME
- Introducing the 2024 TIME100 Next
- The Reinvention of J.D. Vance
- How to Survive Election Season Without Losing Your Mind
- Welcome to the Golden Age of Scams
- Did the Pandemic Break Our Brains?
- The Many Lives of Jack Antonoff
- 33 True Crime Documentaries That Shaped the Genre
- Why Gut Health Issues Are More Common in Women
Write to Justin Worland at justin.worland@time.com